Epigenomics AGFRA:ECX 13 Quick Ratio is 110.25 as of Dec. 2025, which is 1916% above its 10-year median of 5.47. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Epigenomics AG ranks better than 99.53% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Epigenomics AG's quick ratio for the quarter that ended in Dec. 2025 was 110.25.
Epigenomics AG has a quick ratio of 110.25. It generally indicates good short-term financial strength.
The historical rank and industry rank for Epigenomics AG's Quick Ratio or its related term are showing as below:
FRA:ECX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.81 Med: 5.47 Max: 110.25
Current: 110.25
During the past 13 years, Epigenomics AG's highest Quick Ratio was 110.25. The lowest was 1.81. And the median was 5.47.
FRA:ECX's Quick Ratio is ranked better than 99.53% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.715
vs FRA:ECX: 110.25
Epigenomics AG (FRA:ECX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Epigenomics AG Quick Ratio Related Terms
Epigenomics AG Quick Ratio Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Epigenomics AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Epigenomics AG's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a Quick Ratio of 110.25 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Epigenomics AG and its competitors. This is 1916% above median its historical median of 5.47. Over the past decade, Epigenomics AG's Quick Ratio has ranged from 1.81 to 110.25. According to the industry distribution chart, Epigenomics AG ranks #1 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Epigenomics AG's Quick Ratio too high?
Epigenomics AG's current Quick Ratio of 110.25 is 1916% above median its 10-year median of 5.47. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 110.25. The Medical Diagnostics & Research industry median Quick Ratio is 1.72. Epigenomics AG's value of 110.25 is 6328.6% above this industry median. Based on the distribution chart, Epigenomics AG ranks #1 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #1 out of 214 companies for Quick Ratio. This places Epigenomics AG in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.72. Epigenomics AG's value of 110.25 is 6328.6% above this benchmark. Historically, Epigenomics AG's own Quick Ratio has ranged from 1.81 to 110.25 over the past decade. While the company's 10-year median is 5.47 vs. the industry median of 1.72, Epigenomics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.72, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigenomics AG's current Quick Ratio of 110.25 is 6328.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current Quick Ratio is 110.25, which is 1916% above median its own 10-year median of 5.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.87 — trading 866.7% above its estimated fair value. The current Quick Ratio is 110.25, which is 1916% above median its 10-year median of 5.47 and 6328.6% above the Medical Diagnostics & Research industry median of 1.72. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Quick Ratio is 110.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.87 is trading 866.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
Quick Ratio: 110.25 (1916% above median its 10-year median of 5.47)
GF Value™: €0.09 vs. price of €0.87 (866.7% above fair value)
Industry Position: 6328.6% above the Medical Diagnostics & Research median (#1 of 214)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score
Get the complete analysis for FRA:ECX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
